GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
More excellent news today. CF is really delivering on his promises.
Finncap have for the moment retained their 19p target price, but note that their forecasts:
"exclude the potential revenues that would arise from the development of a successful COVID-19 viral challenge model, any othernew challenge models and value for ORPH's non-core assets, including its 49% stake in Imutex and 62.6% stake inPrEP Biopharm."
Bit pointless having that target though, as it is disregarding so much.
Simply Wall St 'Fair Value' for open orphan is 30p, this does not include imutex, prepbio, genomic data or any Covid 19 challenge study gains.
https://simplywall.st/stocks/gb/pharmaceuticals-biotech/aim-orph/open-orphan-shares
Profitability and hVIVO at full capacity are one thing, but once you take off the value of what the company physically owns, then even at this price the mcap is silly (clue - how much is a 24 bed quarantine clinic and virology lab actually worth to buy now in the middle of a global pandemic?).. and then there's Imutec, the genomic database etc etc....
19p target is blown out of the water IMO.
Todays RNS confirms the presentation comments we've all heard.
We're heading towards new territory.
Still, patience required. It wont be overnight. Steady and onward.
It’s building nice for sure
KTRB.
Inline with my calcs.
If the II selling subsides or has subsided, there is very little to hold this back. Remember the government contract RNS is expected to hit this week, hopefully it will be done using part a new 100 bed facility too.
Should be re-rated to 30p then to 50p at minimum